Press Release Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald 11 hours ago
Press Release Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates Aug 17
Press Release Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma Aug 11
Press Release Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board Aug 10